[The clinical evaluation of the hypocholesterolemic effects of an inhibitor of cholesterol synthesis: mevalonic acid].
Twenty eight patients with heterozygous familial hypercholesterolemia were treated with mevalonic acid (an inhibitor of cholesterol synthesis) for 45 days. Patients received a daily dose of 750 to 1500 mg mevalonic acid depending on plasma cholesterol levels. Results showed a significant reduction in cholesterol values whereas no significant difference was observed in HDL cholesterol and triglyceride levels.
Del Nero
E
E
I.N.R.C.A. sede di Genova.
Aloe
N
N
Augeri
C
C
Avola
F
F
Carta
G
G
Cavagnaro
A
A
De Grandi
R
R
Gianfreda
M
M
Magro
G P
GP
Mazzarello
G P
GP
D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008798:Mevalonic Acid / Q000627:therapeutic use*; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood
D000924:Anticholesteremic Agents; D008076:Cholesterol, HDL; D014280:Triglycerides; D002784:Cholesterol; D008798:Mevalonic Acid
Valutazione clinica degli effetti ipocolesterolemizzanti di un inibitore della sintesi del colesterolo: l'acido mevalonico.